Clinical trial: Lack of benefit of MMF in IgAN

Nature Reviews Nephrology 11, 567 (2015). doi:10.1038/nrneph.2015.141 Author: Ellen F. Carney Data from a randomized controlled trial show that mycophenolate mofetil (MMF) did not significantly reduce proteinuria in patients with IgA nephropathy (IgAN) who had failed to respond to initial treatment with lisinopril or losartan plus purified omega-3 fatty acid. The trial was terminated early on

http://feeds.nature.com/~r/nrneph/rss/current/~3/ruMpWuVF-RI/nrneph.2015.141

Source: Nature Reviews Nephrology - August 11, 2015 Category: Urology & Nephrology Authors: Ellen F. Carney Tags: Research Highlight Source Type: research